(Circulation. 2000;101:378.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy
The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study
Correspondence to Project Office, Canadian Cardiovascular Collaboration, 2nd Floor, McMaster Clinic, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada.
Background—Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes.
Methods and Results—Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P=0.01) and LV end-systolic (+19±55 mL [placebo] versus -2±51 mL, P<0.001) volumes after 24 weeks of therapy. LV ejection fraction was unchanged (-0.05% or -0.005) in the placebo group but increased by 2.4% in the metoprolol CR–treated patients (P=0.001). Patients receiving metoprolol CR had a greater decrease in angiotensin II (P=0.036) and renin (P=0.032) levels but an increase in N-terminal atrial natriuretic peptide and brain natriuretic peptide levels (P<0.01). There were fewer deaths in the group receiving ß-blockers (3.4% versus 8.1%), and there was a similar number of patients experiencing the composite outcomes of death or any hospitalization.
Conclusions—When added to ACE inhibitors, angiotensin II receptor antagonists, or both, the use of metoprolol CR improves ventricular function, reduces activation of the renin-angiotensin systems, and results in fewer deaths.
Key Words: heart failure • receptors, adrenergic, beta • hormones • ventricles
This article has been cited by other articles:
 |
|
 |
|
  D. Domanski and E. R. Schwarz Clinical Review: Is the Perioperative Use of {beta}-Blockers Still Recommended? A Critical Review of Recent Controversies Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2009; 14(4): 258 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, and T. Sasaguri Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation Cardiovasc Res, October 1, 2009; 84(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
 |
|
 2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 M. White, J.-L. Rouleau, R. Afzal, J. Floras, S. Yusuf, and R. S. McKelvie Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 113 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J Calvert, A. Shankar, R. J McManus, R. Ryan, and N. Freemantle Evaluation of the management of heart failure in primary care Fam. Pract., April 1, 2009; 26(2): 145 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.V. McMurray, B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, D. L. Keefe, J. Ford, A. Verma, J. Lewsey, and for the Aliskiren Observation of Heart Failure Tre Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, F. G. Spinale, R. Afzal, H. R. Gunasinghe, R. E. Stroud, R. S. McKelvie, and P. P. Liu Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure Eur J Heart Fail, February 1, 2008; 10(2): 125 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Colucci, T. J. Kolias, K. F. Adams, W. F. Armstrong, J. K. Ghali, S. S. Gottlieb, B. Greenberg, M. I. Klibaner, M. L. Kukin, J. E. Sugg, et al. Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial Circulation, July 3, 2007; 116(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure Circulation, February 21, 2006; 113(7): 977 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140. [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 38 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N G Bellenger, K Rajappan, S L Rahman, A Lahiri, U Raval, J Webster, G D Murray, A J S Coats, J G F Cleland, and D J Pennell Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study Heart, July 1, 2004; 90(7): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hryniewicz, A. S. Androne, A. Hudaihed, and S. D. Katz Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure Circulation, August 26, 2003; 108(8): 971 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. St John Sutton, T. Plappert, W. T. Abraham, A. L. Smith, D. B. DeLurgio, A. R. Leon, E. Loh, D. Z. Kocovic, W. G. Fisher, M. Ellestad, et al. Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure Circulation, April 22, 2003; 107(15): 1985 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Krum, E. B. Roecker, P. Mohacsi, J. L. Rouleau, M. Tendera, A. J. S. Coats, H. A. Katus, M. B. Fowler, M. Packer, and for the Carvedilol Prospective Randomized Cumulati Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study JAMA, February 12, 2003; 289(6): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. Anand, D. Judd, A. P. Maggioni, Y.-T. Chiang, M. Bevilacqua, M. Salio, P. Cardano, P. H.J.M. Dunselman, et al. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) Circulation, November 5, 2002; 106(19): 2454 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goldstein Benefits of {beta}-Blocker Therapy for Heart Failure: Weighing the Evidence Arch Intern Med, March 25, 2002; 162(6): 641 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Tsuyuki, R. S. McKelvie, J. M. O. Arnold, A. Avezum Jr, A. C. P. Barretto, A. C. C. Carvalho, D. L. Isaac, A. D. Kitching, L. S. Piegas, K. K. Teo, et al. Acute Precipitants of Congestive Heart Failure Exacerbations Arch Intern Med, October 22, 2001; 161(19): 2337 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy, L. Joseph, and J. L. Rouleau {beta}-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis Ann Intern Med, April 3, 2001; 134(7): 550 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Maggioni HEART FAILURE: Treatment strategies for heart failure: {beta} blockers and antiarrhythmics Heart, January 1, 2001; 85(1): 97 - 103. [Full Text]
|
|
|
|
 |
|
 R. Kelly, A. D Struthers, O. W. Nielsen, J. Hilden, J. Svanegaard, and J. F. Hansen Risk assessment of left ventricular systolic dysfunction in primary care BMJ, July 8, 2000; 321(7253): 111a - 111. [Full Text]
|
|